Dutch Startup Raises €1.7 Million to Bring Hospital-Grade Heart Tests to Your Doctor's Office
Netherlands, Thursday, 19 March 2026.
HeartEye’s breakthrough portable ECG device can perform hospital-quality cardiac diagnostics in under one minute, potentially revolutionizing early heart disease detection outside traditional medical facilities. The funding round, led by ROM InWest with backing from tech industry veterans, will accelerate market introduction of technology that enables general practitioners and nursing homes to conduct professional heart screenings without specialized training or complex equipment.
Healthtech Innovation Addresses Critical Healthcare Gap
This March 2026 funding announcement represents a significant development in the healthtech sector, specifically in cardiac diagnostic technology [1]. HeartEye’s innovation addresses a fundamental challenge in preventive healthcare: making high-quality heart diagnostics accessible outside hospital settings. Currently, creating 12-channel electrocardiograms (ECGs) remains a time-intensive and complex process requiring trained professionals [1]. The startup’s patented mobile 12-channel ECG recorder aims to transform this landscape by enabling rapid, professional-grade cardiac assessments in general practitioner offices and nursing homes [1].
How the Revolutionary Technology Works
HeartEye’s fully wireless ECG recorder represents a breakthrough in portable cardiac diagnostics technology [1]. The handheld, user-friendly device enables general practitioners, assistants, or nurses to complete a 12-channel ECG in less than one minute [1]. The system integrates with a digital platform that allows healthcare providers to share heart recordings with physicians or specialists for interpretation and diagnostic support [1]. This technological approach makes it significantly easier to perform professional, high-quality cardiac diagnostics outside traditional hospital environments [1]. The device’s wireless design and simplified operation eliminate many of the technical barriers that previously limited ECG testing to specialized medical facilities [1].
Investment Details and Strategic Backing
The €1.675 million funding round was led by ROM InWest, a regional investment fund that focuses on Life Sciences & Health innovations in Noord-Holland [1][2]. Notable individual investors participating in the round include Pim Berger, co-founder of Schuberg Philis, and Jeroen Tas, co-founder of Mphasis [1]. Health Innovations, which previously invested in HeartEye, returned as a participant in this second funding round [1]. ROM InWest’s involvement reflects the organization’s strategic focus on supporting companies through the challenging phase between prototype development and market certification, when venture capital firms typically remain hesitant to invest [1].
Market Impact and Healthcare Benefits
HeartEye’s technology addresses two critical healthcare challenges simultaneously: improving early detection of heart conditions while reducing unnecessary healthcare costs [1]. On one hand, the portable ECG system enables earlier identification of heart problems, ensuring patients reach cardiologists when treatment can be most effective [1]. Conversely, the technology helps prevent unnecessary referrals to hospitals, reducing both healthcare expenses and physician workload [1]. This dual benefit contributes to more efficient care delivery, lower overall costs, and reduced pressure on healthcare systems [1]. The innovation brings hospital-grade cardiac diagnostics closer to patients, potentially reducing mortality from heart conditions while making preventive screening more accessible [1].
Funding Allocation and Regulatory Path Forward
The capital injection will support HeartEye through the demanding medical device certification process required under current Medical Device Regulation (MDR) standards [1]. This represents a capital-intensive phase where the company must make substantial investments while being prohibited from clinical use and regular revenue generation [1]. Specific funding allocations include conducting pivotal clinical studies and advancing AI software development [1]. Additionally, HeartEye will focus resources on further developing their digital healthcare platform and establishing production capacity to meet anticipated demand following market approval [1]. This investment timeline reflects the typical challenges facing MedTech innovations, which must navigate complex regulatory requirements before reaching commercial viability [1].